Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10240181 | 0.84 | KMT2A (0.50) | NPSR1KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL24628765 | 0.83 | NPSR1 (0.59) | NPSR1KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL6111591 | 0.80 | S1PR4 (0.62) | NPSR1KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL16975882 | 0.80 | NPSR1 (0.56) | NPSR1KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL11887706 | 0.77 | NPSR1 (0.62) | NPSR1KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL411843 | 0.77 | KMT2A (0.50) | NPSR1KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL10287154 | 0.76 | MAPT (0.43) | NPSR1KMT2ATDP1MEN1MAPT | |
| SCHEMBL10312346 | 0.76 | NPSR1 (0.52) | NPSR1KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL15702327 | 0.75 | NPSR1 (0.51) | NPSR1KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL16673663 | 0.73 | KMT2A (0.57) | NPSR1KMT2ATDP1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-10172827-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172827-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | disclosed |
| EP-2385829-B1 | PRO-NEUROGENIC COMPOUNDS | UNIV TEXAS (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20180127367-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-05-10 | — | — | US | disclosed |
| US-20180127367-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-05-10 | — | — | US | disclosed |
| US-20180127367-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-05-10 | — | — | US | disclosed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-8362277-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362277-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362277-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20110015217-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-20 | — | — | US | disclosed |
| US-20110015217-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-20 | — | — | US | disclosed |
| US-20110003836-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-06 | — | — | US | disclosed |
| US-20110003836-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BDNF, GAP43, DCX | NPSR1 149/4885KMT2A 3749/4885TDP1 352/4885 |
| US-10172827-B2 | Pro-neurogenic compounds | DCX, GAP43, BDNF | NPSR1 81/4885KMT2A 2693/4885TDP1 2607/4885 |
| US-20180127367-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | NPSR1 149/4885KMT2A 3749/4885TDP1 352/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | NPSR1 149/4885KMT2A 3749/4885TDP1 352/4885 |
| US-20110015217-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | NPSR1 81/4885KMT2A 2693/4885TDP1 2607/4885 |
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | NPSR1 285/4885KMT2A 3598/4885TDP1 346/4885 |
| US-20110003836-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | NPSR1 86/4885KMT2A 2838/4885TDP1 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.